Recombinant Rabbit monoclonal primary
Kininogen 1 Recombinant Rabbit Monoclonal Antibody [JE43-72] (ET7109-34)
Recombinant protein within human kininogen 1 aa 500-644.
Human liver tissue, human kidney tissue, mouse stomach lysate.
Store at +4C after thawing. Aliquot store at -20C. Avoid repeated freeze / thaw cycles.
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A purified.
Predicted molecular weight: 48, 72 kDa
Alpha-2-thiol proteinase inhibitor antibody; BDK antibody; BK antibody; Bradykinin antibody; Bradykinin included antibody; Fitzgerald factor antibody; FLAUJEAC FACTOR antibody; High molecular weight kininogen antibody; HMWK antibody; Ile-Ser-Bradykinin antibody; Kallidin I antibody; Kallidin II antibody; KNG antibody; KNG1 antibody; KNG1_HUMAN antibody; Low molecular weight growth-promoting factor antibody; WILLIAMS FACTOR antibody; Williams-Fitzgerald-Flaujeac factor antibody
Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
Bradykinin is released from kininogen by plasma kallikrein.; Hydroxylation of Pro-383 occurs prior to the release of bradykinin.; Phosphorylated by FAM20C in the extracellular medium.; N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.